Who are Tvardi Therapeutics, Inc.'s main suppliers?

Tvardi Therapeutics, Inc. (TVRD) key suppliers include: VENDOR-A, VENDOR-B, BAYLOR-COLLEGE-OF-MEDICINE, NATIONAL-INSTITUTES-OF-HEALTH, STEM-MED-LIMITED-PARTNERSHIP and 2 more. View the full supplier network at chainsifter.com/chain/TVRD.

Who are Tvardi Therapeutics, Inc.'s major customers?

Tvardi Therapeutics, Inc. (TVRD) key customers include: HUTCHMED-CHINA-LIMITED, AstraZeneca PLC, AstraZeneca PLC, Eli Lilly and Company, Eli Lilly and Company and 8 more. View the full customer network at chainsifter.com/chain/TVRD.

What sector is Tvardi Therapeutics, Inc. in?

Tvardi Therapeutics, Inc. (TVRD) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Tvardi Therapeutics, Inc. Supplier List (TVRD): 7 Verified Suppliers

7Suppliers

13Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Tvardi Therapeutics, Inc. (TVRD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

3Distinct source URLs

9High confidence

0.764Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Tvardi Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
VENDOR-A	VENDOR-A	92%	Vendor A accounted for 41% of operating expenses and 72% of accounts payable as of March 31, 2026
VENDOR-B	VENDOR-B	92%	Vendor B accounted for 7% of operating expenses and 10% of accounts payable as of March 31, 2026
BAYLOR-COLLEGE-OF-MEDICINE	BAYLOR-COLLEGE-OF-MEDICINE	85%	Under the BCM First Agreement, we obtained an exclusive, worldwide, sublicensable license under BCM's rights to certain patents in oncology and certain non-oncology indications (BCM Patent Rights), t…
NATIONAL-INSTITUTES-OF-HEALTH	NATIONAL-INSTITUTES-OF-HEALTH	80%	Under the BCM Second Agreement, we obtained an exclusive, worldwide, sublicensable license under certain patents and patent applications co-owned by BCM and the National Institutes of Health (NIH)
STEM-MED-LIMITED-PARTNERSHIP	STEM-MED-LIMITED-PARTNERSHIP	80%	StemMed assigned the BCM First Agreement to us in connection with the transfer of all or substantially all of the assets and businesses to which the BCM First Agreement relates
ORANY	ORANY	72%	ary representations and warranties by the parties, a grant to Patheon of certain limited license rights to Cara’s intellectual property in connection with Patheon’s performance of the services under …
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from TVRD graph: ary representations and warranties by the parties, a grant to Patheon of certain limited license rights to Cara’s in…

Tvardi Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
HUTCHMED-CHINA-LIMITED	HUTCHMED-CHINA-LIMITED	90%	development of multiple oncology programs including surufatinib (Sulanda) at HUTCHMED (China) Limited and ramucirumab (Cyramza) for HCC at Eli Lilly and Company
AZN	AstraZeneca PLC	72%	pharmaceutical Industry Our business is highly dependent on the success of our product candidates, TTI-101, TTI-109 and any other product candidates that we advance into the clinic. All of our prod…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from TVRD graph: Reciprocal relationship from AZN graph: Reciprocal relationship from TVRD graph: pharmaceutical Industry Our busines…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from TVRD graph: pharmaceutical Industry Our business is highly dependent on the success of our product candidates, TTI-101, TTI-109 …
LLY	Eli Lilly and Company	72%	pharmaceutical Industry Our business is highly dependent on the success of our product candidates, TTI-101, TTI-109 and any other product candidates that we advance into the clinic. All of our prod…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from TVRD graph: Reciprocal relationship from MRK graph: Reciprocal relationship from TVRD graph: Reciprocal relationship from MRK grap…
MRK	Merck & Co., Inc.	72%	pharmaceutical Industry Our business is highly dependent on the success of our product candidates, TTI-101, TTI-109 and any other product candidates that we advance into the clinic. All of our prod…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from TVRD graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TVRD graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	of $50.0 million for the purchase of an aggregate of 244,963 shares of Cara common stock at a price of $204.11 per share, which represented a premium over a pre-determined average closing price of th…
BMY	Bristol-Myers Squibb Company	62%	Reciprocal relationship from BMY graph: Reciprocal relationship from TVRD graph: pharmaceutical Industry Our business is highly dependent on the success of our product candidates, TTI-101, TTI-109 …
BRISTOL-MYERS-SQUIBB-CO	BRISTOL-MYERS-SQUIBB-CO	62%	pharmaceutical Industry Our business is highly dependent on the success of our product candidates, TTI-101, TTI-109 and any other product candidates that we advance into the clinic. All of our prod…
CARA-THERAPEUTICS-INC	CARA-THERAPEUTICS-INC	62%	t claim or to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “…
ROCHE-HOLDING-AG	ROCHE-HOLDING-AG	62%	pharmaceutical Industry Our business is highly dependent on the success of our product candidates, TTI-101, TTI-109 and any other product candidates that we advance into the clinic. All of our prod…

Tvardi Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TVRD-DEBT-13152	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
TVRD-DEBT	Debt stack $174,000	90%	Market cache reports total debt of $174,000.

Tvardi Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Tvardi Therapeutics, Inc..

Tvardi Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
TVRD-OWNER-DANSKE-BANK-A-S	DANSKE BANK A/S	90%	13F overlay lists DANSKE BANK A/S as top holder; 1 tracked holders.

Tvardi Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
DYN	Dyne Therapeutics, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
DEO	Diageo plc	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2

Tvardi Therapeutics, Inc. Supply Chain